Marea Therapeutics utilizes large-scale human genetic data and adipocyte biology to develop therapies targeting remnant cholesterol, a key driver of cardiometabolic diseases. Their lead program, MAR001, is a monoclonal antibody designed to lower remnant cholesterol levels, addressing a critical unmet need for patients at high risk of cardiovascular events despite existing treatments.
Funding
$190M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PAVPFounders
Product
Problem
Despite existing treatments targeting traditional risk factors like LDL cholesterol and obesity, many individuals remain at high risk for cardiovascular events due to elevated remnant cholesterol levels. There are currently no targeted therapies specifically designed to lower remnant cholesterol, a key driver of cardiometabolic diseases. This unmet need leaves a significant patient population vulnerable to heart attacks and related complications.
Solution
Marea Therapeutics is developing first-in-class therapies that target the underlying biology of cardiometabolic diseases by focusing on remnant cholesterol. Their lead program, MAR001, is a monoclonal antibody that inhibits ANGPTL4, a protein highly expressed in adipose tissue. By inhibiting ANGPTL4, MAR001 aims to augment lipoprotein lipase (LPL) activity, which lowers remnant cholesterol and improves adipose tissue function. This approach addresses the dysfunction in adipose tissue that leads to elevated remnant cholesterol and metabolic dysfunction, ultimately reducing the risk of heart attack. Marea's therapies have the potential to complement existing treatments and provide transformative options for patients with cardioendocrine diseases.
Target Audience
The primary target audience includes patients with elevated remnant cholesterol levels who remain at high risk for cardiovascular events despite existing treatments, as well as physicians specializing in cardiology, endocrinology, and metabolic disorders.
Features
- MAR001: A monoclonal antibody targeting ANGPTL4 to lower remnant cholesterol levels.
- ANGPTL4 Inhibition: Augments lipoprotein lipase (LPL) activity to improve adipose tissue function.
- Genetically Validated Target: Leverages human genetic data identifying ANGPTL4 as a promising therapeutic target.
- Preclinical Validation: Demonstrated reduction in triglycerides, remnant cholesterol, and ectopic fat, along with improved insulin sensitivity in preclinical models.
- Phase 2 Clinical Development: MAR001 is currently in Phase 2 clinical trials for adults with metabolic dysfunction.